Pricing Log in Create free account
Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

905.02 2.12 +0.23%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. 10-Q filed Apr 29, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 6:54 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 28, 2025: 15 added · 24 removed · 39 modified; 3 with only figures updated

  1. Modified

    •competing drugsproducts and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") (including biosimilar versions of Regeneron's Products);